Csenge Advisory Group Cuts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Csenge Advisory Group trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 41.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,431 shares of the biopharmaceutical company’s stock after selling 5,932 shares during the period. Csenge Advisory Group’s holdings in Gilead Sciences were worth $618,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Etesian Wealth Advisors Inc. grew its stake in shares of Gilead Sciences by 0.7% in the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after buying an additional 128 shares in the last quarter. Financial Counselors Inc. grew its stake in shares of Gilead Sciences by 1.5% in the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after buying an additional 128 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Gilead Sciences by 3.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 130 shares in the last quarter. Steph & Co. grew its stake in shares of Gilead Sciences by 1.9% in the 4th quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock worth $611,000 after buying an additional 142 shares in the last quarter. Finally, First Affirmative Financial Network grew its stake in shares of Gilead Sciences by 3.5% in the 1st quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock worth $318,000 after buying an additional 147 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. UBS Group lowered their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Morgan Stanley lowered their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Royal Bank of Canada restated a “sector perform” rating and issued a $74.00 target price on shares of Gilead Sciences in a report on Monday, July 1st. Finally, HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price for the company in a report on Wednesday, April 24th. Twelve analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $84.00.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.29% of the company’s stock.

Gilead Sciences Stock Up 1.9 %

Shares of NASDAQ:GILD traded up $1.32 during trading hours on Thursday, hitting $70.07. The company’s stock had a trading volume of 4,216,285 shares, compared to its average volume of 7,475,613. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The company has a market capitalization of $87.30 billion, a price-to-earnings ratio of 192.25, a P/E/G ratio of 2.87 and a beta of 0.18. The firm’s fifty day moving average price is $66.23 and its 200 day moving average price is $71.88.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. During the same quarter in the previous year, the business posted $1.37 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, research analysts expect that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.40%. The ex-dividend date of this dividend was Friday, June 14th. Gilead Sciences’s payout ratio is currently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.